Sesen Bio, Inc. (SESN) Analysts See $-0.12 EPS

July 14, 2018 - By Robert Sims

Analysts expect Sesen Bio, Inc. (NASDAQ:SESN) to report $-0.12 EPS on August, 13.They anticipate $0.18 EPS change or 60.00 % from last quarter’s $-0.3 EPS. After having $-0.11 EPS previously, Sesen Bio, Inc.’s analysts see 9.09 % EPS growth. It closed at $2 lastly. It is down 17.57% since July 14, 2017 and is uptrending. It has outperformed by 5.00% the S&P500.

Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. The company has market cap of $153.00 million. It develops its products based on its Targeted Protein Therapeutics platform. It currently has negative earnings. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer.

More news for Sesen Bio, Inc. (NASDAQ:SESN) were recently published by:, which released: “Pre-Open Movers 07/09: (MBVX) (HELE) (GRPN) Higher; (CTIC) (PETS) (PG) Lower (more…)” on July 09, 2018.‘s article titled: “Premarket analyst action – healthcare” and published on July 09, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: